Evidence map›Paper›PMID 39614818›Full record

ArticleJournal of medicinal chemistry2024

Design, Synthesis, and Biological Evaluation of [1,2,5]Oxadiazolo[3,4-

Mary A Foutz, Emily L Krinos, Martina Beretta, Stefan R Hargett, Riya Shrestha, Jacob H Murray, Ethan Duerre, Joseph M Salamoun, Katrina McCarter, Divya P Shah and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mary A FoutzDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.
Emily L KrinosDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.
Martina BerettaSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2033, Australia.
Stefan R HargettDepartments of Pharmacology and Medicine, University of Virginia, Charlottesville, Virginia 22908, United States.
Riya ShresthaSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2033, Australia.
Jacob H MurrayDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.
Ethan DuerreDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.
Joseph M SalamounDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.
Katrina McCarterDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.
Divya P ShahSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2033, Australia.
Kyle L HoehnSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2033, Australia.
Webster L SantosDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States.ORCID 0000-0002-4731-8548

Funding

Therapeutic Mitochondrial UncouplersR01DK128612 · NIDDK · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI HOEHN, KYLE LEE, SANTOS, WEBSTER L · 2021 to 2024
$2.2M
NIDDK NIH HHS R01 DK128612
6 · The paper itself

Abstract

Mitochondrial uncouplers are small molecule protonophores that act to dissipate the proton motive force independent of adenosine triphosphate (ATP) synthase. Mitochondrial uncouplers such as BAM15 increase respiration and energy expenditure and have potential in treating a variety of metabolic diseases. In this study, we disclose the structure-activity relationship profile of 6-substituted [1,2,5]oxadiazolo[3,4-

Indexed as

Drug DesignObesityOxadiazolesAnimalsFatty LiverHumansMaleMiceMice, Inbred C57BLMitochondriaPyridinesStructure-Activity RelationshipUncoupling AgentsOxadiazolesPyridinesUncoupling Agents

Identifiers

PMID39614818
PMCPMC11647902

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.